Literature DB >> 23089909

Significance of preoperative tissue levels of vascular-endothelial cadherin, liver-intestine cadherin and vascular endothelial growth factor in gastric cancer.

Kum Hei Ryu1, Ki-Nam Shim, Sung-Ae Jung, Kwon Yoo, Yang-Hee Joo, Joo Ho Lee.   

Abstract

BACKGROUND/AIMS: The aims of this study were to examine the expressions of endothelium specific VE-cadherin, intestine specific LI-cadherin, and vascular endothelial growth factor (VEGF), and to determine their relationships with the clinicopathological parameters of gastric cancer.
METHODS: A total 47 patients with gastric cancer who underwent surgery were enrolled. Endoscopic biopsies were obtained from the cancer and normal mucosa, respectively. Using semiquantitative RT-PCR, the mRNA expression levels of VE-cadherin, LI-cadherin and VEGF were measured by tumor/normal (T/N) ratios. The protein expressions of VE-cadherin, LI-cadherin and VEGF were examined by Western blot and immunohistochemical stain in surgically resected tissues. The clinicopathological variables were reviewed and analyzed, retrospectively.
RESULTS: Twenty two cases (46.8%) of VE-cadherin, 25 cases (53.2%) of LI-cadherin and 27 cases (51.1%) of VEGF mRNA expressions were overexpressed in gastric cancer compared to normal tissue. There was a tendency for T/N ratio of VE-cadherin mRNA to correlate with the lymphatic invasion (p=0.07) and the lymph node metastasis (p=0.099) in advanced gastric cancer. The T/N ratio of LI-cadherin mRNA showed significant association with distant metastasis (p=0.031) and lymphatic invasion especially in advanced gastric cancer (p=0.023). There was a tendency for the T/N ratio of VEGF mRNA to correlate with the distant metastasis (p=0.073) in advanced gastric cancer.
CONCLUSIONS: As increased mRNA expression of LI-cadherin was associated with distant metastasis and lymphatic invasion especially in the biopsy specimen of advanced gastric cancer before surgery, it may provide useful preoperative information on tumor aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23089909     DOI: 10.4166/kjg.2012.60.4.229

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  5 in total

1.  The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer.

Authors:  C J Wang; P J Tong; M Y Zhu
Journal:  Clin Transl Oncol       Date:  2015-09-14       Impact factor: 3.405

Review 2.  Molecular targeting to treat gastric cancer.

Authors:  Keishiro Aoyagi; Kikuo Kouhuji; Junya Kizaki; Taro Isobe; Kousuke Hashimoto; Kazuo Shirouzu
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

3.  Aberrant loss of dickkopf-3 in gastric cancer: can it predict lymph node metastasis preoperatively?

Authors:  Joong-Min Park; Mi Kyung Kim; Kyong-Choun Chi; Jae Hyung Kim; Sang-Hoon Lee; Eun-Ju Lee
Journal:  World J Surg       Date:  2015-04       Impact factor: 3.352

4.  Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer.

Authors:  Keishiro Aoyagi; Kikuo Kouhuji; Motoshi Miyagi; Junya Kizaki; Taro Isobe; Kousuke Hashimoto; Kazuo Shirouzu
Journal:  World J Crit Care Med       Date:  2013-11-04

Review 5.  Possible roles of LI-Cadherin in the formation and maintenance of the intestinal epithelial barrier.

Authors:  Werner Baumgartner
Journal:  Tissue Barriers       Date:  2013-01-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.